1. Home
  2. XBIT vs FLYX Comparison

XBIT vs FLYX Comparison

Compare XBIT & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

SELL

Current Price

$2.15

Market Cap

69.8M

Sector

Health Care

ML Signal

SELL

Logo flyExclusive Inc.

FLYX

flyExclusive Inc.

HOLD

Current Price

$1.16

Market Cap

62.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
FLYX
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
62.1M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
XBIT
FLYX
Price
$2.15
$1.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
37.4K
★ 229.3K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 5.61
EPS
N/A
★ N/A
Revenue
N/A
★ $375,877,000.00
Revenue This Year
N/A
$8.30
Revenue Next Year
$30.47
$15.15
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 14.85
52 Week Low
$2.09
$1.05
52 Week High
$3.44
$8.88

Technical Indicators

Market Signals
Indicator
XBIT
FLYX
Relative Strength Index (RSI) 39.61 41.78
Support Level N/A $1.11
Resistance Level $2.46 $1.37
Average True Range (ATR) 0.07 0.08
MACD -0.00 -0.01
Stochastic Oscillator 0.00 7.14

Price Performance

Historical Comparison
XBIT
FLYX

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About FLYX flyExclusive Inc.

flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.

Share on Social Networks: